Embecta (NASDAQ:EMBC) Director Sells $37,002.84 in Stock

Embecta Corp. (NASDAQ:EMBC) Director Milton Mayo Morris sold 6,293 shares of Embecta stock in a transaction on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the transaction, the director directly owned 53,828 shares of the company’s stock, valued at approximately $316,508.64. This trade represents a 10.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Embecta Stock Performance

NASDAQ EMBC opened at $4.89 on Friday. The firm has a 50-day moving average of $4.29 and a 200-day moving average of $5.69. The stock has a market cap of $277.07 million, a PE ratio of 3.30 and a beta of 0.86. Embecta Corp. has a 52-week low of $2.77 and a 52-week high of $15.55.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to the consensus estimate of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The firm’s quarterly revenue was down 8.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, analysts predict that Embecta Corp. will post 1.84 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be paid a $0.01 dividend. The ex-dividend date is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. Embecta’s dividend payout ratio is 2.70%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. Finally, Bank of America lowered their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $11.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Brooklyn Investment Group increased its stake in Embecta by 5.9% in the 4th quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock valued at $234,000 after buying an additional 1,098 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after buying an additional 1,110 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Embecta by 1.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock worth $1,785,000 after buying an additional 1,520 shares during the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after acquiring an additional 1,574 shares in the last quarter. 93.83% of the stock is owned by institutional investors.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.